Literature DB >> 11285430

Surgical therapy for dialysis-related spondyloarthropathy: review of 30 cases.

E Shiota1, M Naito, K Tsuchiya.   

Abstract

Surgical therapy for dialysis-related spondyloarthropathy was investigated regarding its spinal manifestation. Between August 1985 and May 1998, 31 operations were performed on 16 male and 14 female patients; of these, 17 had cervical and 13 had lumbar spinal disorders. The average patient age was 59 years. The average period of hemodialysis was 14.8 years. Twenty-eight of 30 patients had cystic bone lesions and 24 had carpal tunnel syndrome. Four major postoperative complications occurred: death from paralysis and respiratory distress, severe kyphosis from the collapse of the grafted bone, deep infection from instrumentation, and wire breakage and bone fusion failure. Postoperative results with an average follow-up period of 2.7 years were good in 19 cases (63%), fair in 8 cases (27%), and poor in 3 cases (10%). As yet, surgical intervention for dialysis-related spondyloarthropathy is still regarded as a noncurative treatment; furthermore, the anterior approach to the cervical spine has a high risk for postoperative complications.

Entities:  

Mesh:

Year:  2001        PMID: 11285430     DOI: 10.1097/00002517-200104000-00012

Source DB:  PubMed          Journal:  J Spinal Disord        ISSN: 0895-0385


  3 in total

1.  Inpatient Outcomes in Dialysis Dependent Patients Undergoing Elective Cervical Spine Surgery for Degenerative Cervical Conditions.

Authors:  Sean M Mitchell; Anthony M White; David H Campbell; Andrew Chung; Norman Chutkan
Journal:  Global Spine J       Date:  2019-10-17

2.  Surgical management of cervical spondyloarthropathy in hemodialysis patients.

Authors:  Panayiotis Spinos; Charalambos Matzaroglou; Meni Partheni; Angeliki Deli; Menelaos Karanikolas; Dimitrios Konstantinou
Journal:  Open Orthop J       Date:  2010-01-19

Review 3.  [Osteomyelitis of the spine].

Authors:  E J Müller; O J Russe; G Muhr
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.